Navigation Links
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Date:4/21/2009

y forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                      Media
    info@peregrineinc.com                          Barbara Lindheim
    (800) 987-8256                                (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
2. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
3. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
4. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
5. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
6. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
9. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
10. Oridion Announces Significant Medical Studies Presented at STA
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... Phase 3 registration clinical trial for KRX-0401 ... relapsed / refractory multiple myeloma patients. ,, ... Study to Assess the Efficacy and Safety ... Bortezomib (Velcade®) and Dexamethasone in Multiple Myeloma ...
(Date:12/16/2009)... , - MIVI-TRUST ... Total of Over,640 patients Ahead of Schedule ... (Euronext Brussels: THR), a biopharmaceutical company,focused on ... for eye,disease, vascular disease and cancer, announces ... the second Phase III trial evaluating microplasmin ...
(Date:12/15/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that it will release its fiscal ... after the market close. The Company will host a ... a.m. (Eastern Time) to discuss the results. ... call by dialing 1-888-324-9321 (Passcode: BLUD). Investors can also ...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4RES Q Labor Resource Management Scores the Highest Among Staff Nurse Scheduling System Solutions Analyzed in the 2009 KLAS Mid term Performance Review 51064 1RES Q Labor Resource Management Scores the Highest Among Staff Nurse Scheduling System Solutions Analyzed in the 2009 KLAS Mid term Performance Review 51064 2Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 1Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 2Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 3Actor Chris Noth to Share Story of Loss in National Life Insurance Awareness Month 51054 1Actor Chris Noth to Share Story of Loss in National Life Insurance Awareness Month 51054 2Actor Chris Noth to Share Story of Loss in National Life Insurance Awareness Month 51054 3
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), the ... that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII ... (20 mg X 2), did not alter the median time ... to be reached in the subjects evaluated. In the ...
... trials begin enrollment in May 2009; Reinforces Lilly,s commitment ... 21 Eli Lilly and Company (NYSE: ... this month in two separate but identical Phase III ... an anti-amyloid beta monoclonal antibody being investigated as a ...
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 2Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 3Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 4Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 5
(Date:12/16/2009)... - TSO3 Inc. ("TSO3") (TSX: TOS) and 3M ... reached for 3M to be the exclusive supplier ... partnership with TSO3, an innovator in low temperature ... through the use of ozone, will include new ... global sales channel. This agreement, combined with recent ...
(Date:12/16/2009)... with the Weatherhead 100 Upstart Award on December 3, 2009. ... and is a testament to hard work, commitment, innovation and the ... ... December 16, 2009 -- Request A Test, Ltd. is proud to ... 3, 2009. The Weatherhead 100 showcases the fastest growing companies ...
(Date:12/16/2009)... time for the Christmas rush Hallmark Cards have announced a ... the industry. With an easy to navigate website at www.hallmark.co.uk/specialoccasions ... thank you with their own words and photos and then order ... , ... Bradford, UK (PRWEB) December 16, 2009 -- ...
(Date:12/16/2009)... in all of the Florida Whole Foods store. , ... ... hair transplant and hair loss physician , is pleased to announce ... Protein Shake. Dr. Shapiro developed the all natural growth-hormone free, hair ... out and muscle building., , , , ,The Whole Foods grocery chain ...
(Date:12/15/2009)... The failure of the U.S. Senate to allow ... less the more effective direct bulk purchasing of ... how big industry controls the health reform debate, ... by Senator Dorgan (D-ND) was a relatively modest ... allow Medicare to directly negotiate discounts with drug ...
Breaking Medicine News(10 mins):Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 2Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 4Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 2Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 3Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 4Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3
... over the world for cosmetic purposes might also improve ... severely hurt and scarred during combat. Dr. Adam Katz, ... Health System, will conduct research in this area under ... House officials will announce the formation of AFIRM, which ...
... 17 The National Center for,Autism Research and ... research, education and family support,services has enrolled its ... NCARE resulting from the announcement to begin enrollment ... desperately need centralized,autism resources., Soonhee "Sunny" Bailey, ...
... Meeting Will Provide Healthcare Leaders With Information ... Cuts for HAIs, WASHINGTON, April 17 ... Services (CMS) regulations that will eliminate or,reduce ... be the,subject of a two-day conference for ...
... The National,Association of Specialty Health Organizations ... Innovation Award. The recipient of the award,will ... through,innovative programs and practices., (Logo: ... for the specialty health industry, we felt ...
... 17 MSA (NYSE: MSA ), the,global leader ... protect people,s health and safety, announced today that it,will ... via the,Internet on Thursday, May 1, 2008 at 10:00 ... Investors and interested parties will have the opportunity to ...
... YORK, April 17 Bristol-Myers Squibb,Company (NYSE: BMY ... 2008 on,Thursday, April 24. During a 10:30 a.m. (ET) ... information and will address,inquiries from investors and analysts., ... to a live,webcast of the call at http://www.bms.com/ir ...
Other Medicine News:Health News:UVA Health System part of Armed Forces multi-million dollar effort to help soldiers 2Health News:California's First Non-profit Center for Autism Research, Education and Family Services 2Health News:APIC Conference to Address New CMS Regulations 2Health News:The National Association of Specialty Health Organizations to Recognize Excellence in Technology Education With Industry Award 2Health News:MSA Schedules First Quarter Earnings Webcast 2
The ABI PRISM 3100 Genetic Analyzer, a multi-color fluorescence-based DNA analysis system with 16 capillaries operating in parallel, offers high-quality data and efficient sample processing for the b...
... latest 3-part differential analyzer based on the ... the CELL-DYN line. Offering 18 parameters and ... CELL-DYN 1800 meets the needs to today's ... than its predecessors and fits under standard ...
... QC Manager Point-of-Care Data Management System provides ... Glucose Testing System and the Precision PCx. ... automated way to collect, analyze, and report ... It provides an essential laboratory tool for ...
... Test is a color immunochromatographic assay using ... labeled color particles coated at two separate ... greater sensitivity than the conventional single label ... procedure, a throat swab is subjected to ...
Medicine Products: